healthcare

healthcare Articles

The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
The October 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Biotech company Moderna has filed with the SEC regarding its initial public offering.
Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination regimens in multiple cancer settings.
Eli Lilly released better-than-expected third-quarter financial results before the markets opened on Tuesday.
Regulus Therapeutics shares shot up on Tuesday after the company announced that it had amended and restructured its collaboration and license agreement with Sanofi.
Medical technology company Vapotherm intends to price 4 million shares for and initial public offering valued up to more than $73 million.
Eli Lilly is scheduled to release its most recent quarterly results before the markets open on Tuesday.
Clearside Biomedical shares were halved early on Monday after the firm reported results from its late-stage Sapphire trial.
Alkermes shares dropped early on Friday after the company anncounced the results from its most recent meeting with the U.S. Food and Drug Administration.
Teva Pharmaceutical released its most recent earnings report before the markets opened on Thursday.
KemPharm shares made a handy gain on Wednesday after the firm announced a new license agreement with KVK Tech for the U.S. commercial rights of its FDA-approved prodrug product, Apadaz.
Acadia Pharmaceuticals shares dipped on Wednesday despite announcing positive top-line results from its Clarity mid-stage study in major depressive disorder (MDD).
Merck shares were up slightly on Wednesday after the pharma giant gave another key update for its KEYTRUDA line. The firm announced that the U.S. Food and Drug Administration (FDA) has approved...
Pfizer reported mixed quarterly results before the markets opened on Tuesday and shares retreated in the premarket.